Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

SYGNIS Granted European and US Patent for Drug Screening Platform

Published: Tuesday, April 23, 2013
Last Updated: Tuesday, April 23, 2013
Bookmark and Share
The patents protect a new procedure for screening and characterizing drugs in development, based on detection of protein-protein interactions.

SYGNIS Pharma AG has been granted the European and US patent for a new basic technology for the detection of protein-protein interactions, a screening platform for the development of novel drugs.

In the words of SYGNIS’ CEO, Pilar de la Huerta, “the technology will be licensed to a distribution partner and we expect to see our first revenues during the current financial year 2013.”

Protein-protein interactions falls within the scope of proteomics, a field that is growing in importance for research into new customized drugs.

SYGNIS’ new platform can be used to improve the characterization of new drugs in development and identification of new therapeutic targets.

SYGNIS’ technology will increase the potential for generating better drugs within the customized drug development field. Following its merger with the Spanish company X-Pol, which forms part of the GENETRIX Group, SYGNIS aims to become a key player in the growing market for molecular tools and personalized medicine.

SYGNIS aims to use these patents, together with its recent company restructuring and successful implementation of the polymerase QualiPhi™, to enhance the impetus it announced on its merger with X-Pol and become a prominent player in the growing market for new DNA tools and customized drugs, a sector that has seen a two-digit growth rate over the last few years.

According to sources from SYGNIS, this transformation will enable it to obtain its first revenues in 2013 and operating profit in successive years.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,300+ scientific posters on ePosters
  • More Than 4,900+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

SYGNIS and GENETRIX Sign a Binding Term Sheet
Proposed combination of businesses of SYGNIS and GENETRIX’ subsidiary X-Pol.
Monday, July 23, 2012
Scientific News
Breakthrough Flu Vaccine Inhibited by Pre-existing Antibodies
Universal truths – how existing antibodies are sabotaging the most promising new human flu vaccines.
Researchers Develop Software That Could Facilitate Drug Development
AptaTRACE can identify aptamers, potentially speed drug advancement.
Gene Therapy for Metabolic Liver Diseases
Researchers have tested gene therapy in pigs from hereditary tyrosinemia type 1, with corrected liver cells being transplanted into the diseased liver.
Zika Vaccine Candidates Show Promise
Two experimental vaccines have shown promise against a major viral strain responsible for the Brazilian Zika outbreak.
New Medication Shows Promise Against Liver Fibrosis in Animal Studies
Liver fibrosis is a gradual scarring of the liver that puts people at risk for progressive liver disease and liver failure.
Raw Eggs Deemed Safe to Eat
A report published today by the Advisory Committee on the Microbiological Safety of Food (ACMSF) into egg safety has shown a major reduction in the risk from salmonella in UK eggs.
Monitoring TTX Toxin in Shellfish
In a number of small studies, mussels and oysters from the eastern and northern part of the Oosterschelde in Holland were found to contain tetrodotoxin (TTX).
Gene Terapy for Muscle Wasting Developed
New gene therapy could save millions of people suffering from muscle wasting disease.
NIH Begins Yellow Fever Vaccine Trial
NIH has initiated an early-stage clinical trial of a vaccine to protect against yellow fever.
Gene-Editing 'Toolbox' Targets Multiple Genes Simultaneously
Researchers have designed a system that modifies, or edits, multiple genes in a genome at once while minimising unintentional effects.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,300+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,900+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!